Objectives The aims of this study were to examine the effects of genetic and clinical factors
on the maintenance dose of tacrolimus in patients following renal transplantation and to …

Kidney transplant recipients carrying the CYP3A5* 1 allele have lower tacrolimus troughs,
and higher dose requirements compared to those with the CYP3A5* 3/* 3 genotype …

High inter-individual variability in tacrolimus clearance is attributed to genetic
polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by …

ABSTRACT​ Introduction: As tolerance is not yet achievable, the kidney-transplanted-
patients have to take on a daily-basis immunosuppressive drugs in order to avoid acute …

Tacrolimus (TAC) is a first‐line immunosuppressant used to prevent organ rejection after
kidney transplantation. There is large inter‐individual variability in its pharmacokinetics …

The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

We investigated how cytochrome P450 (CYP) 3A5 polymorphism affects pharmacokinetics
of tacrolimus and its interaction with diltiazem in Chinese kidney transplant recipients. Sixty …

Kidney transplantation requires lifelong immunosuppression with agents that prevent
allograft rejection. Immunosuppressive regimens typically include a steroid, an immune …

Background Tacrolimus is a widely prescribed immunosuppressant agent for kidney
transplantation. However, optimal dosing is challenging due to its narrow therapeutic index …

Immunosuppression management in kidney transplantation has evolved to include an
increasingly diverse choice of medications. Although informed by patient and donor …